Publications en collaboration avec des chercheurs de Harvard Medical School (7)

2024

  1. Clonal competition assays identify fitness signatures in cancer progression and resistance in multiple myeloma

    HemaSphere, Vol. 8, Núm. 7

2023

  1. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

    Nature Medicine, Vol. 29, Núm. 9, pp. 2259-2267

  2. Improving NK cell function in multiple myeloma with NKTR-255, a novel polymer-conjugated human IL-15

    Blood Advances, Vol. 7, Núm. 1, pp. 9-19

2020

  1. Clinical features associated with COVID-19 outcome in multiple myeloma: First results from the International Myeloma Society data set

    Blood, Vol. 136, Núm. 26, pp. 3033-3040

2019

  1. Dual PAK4-NAMPT inhibition impacts growth and survival, and increases sensitivity to DNA-damaging agents in Waldenstrom € macroglobulinemia

    Clinical Cancer Research, Vol. 25, Núm. 1, pp. 369-377

2017

  1. Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma

    Blood, Vol. 129, Núm. 16, pp. 2233-2245

2015

  1. Deep Response in Multiple Myeloma: A Critical Review

    BioMed Research International, Vol. 2015